Thymosin Alpha-1

Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide originally isolated from thymic tissue by Goldstein and colleagues in the 1970s. It is an N-terminally acetylated, naturally occurring thymic peptide that plays a central role in immune-system maturation and regulation in research models. Tα1 has been characterized under the trade name Zadaxin as an immunomodulatory research reference compound, with historical investigation in chronic hepatitis B research models and as an adjunct in cancer immunotherapy research.

The immunomodulatory mechanism of Tα1 involves activation of Toll-like receptors (TLR2 and TLR9) on dendritic cells, leading to enhanced antigen presentation, T-cell priming, and maturation of functional T-helper and cytotoxic T-cell populations in preclinical systems. Research has demonstrated that Tα1 promotes the differentiation of CD4+ and CD8+ T-cells, enhances natural killer cell cytotoxicity markers, and increases the production of interferon-alpha and interferon-gamma in cell-culture models. The peptide also modulates inflammatory-marker responses by balancing pro- and anti-inflammatory cytokine markers in preclinical studies.

Extensive preclinical research has examined Tα1 in the context of viral-infection research models, including hepatitis B, hepatitis C, and HIV preclinical models. Studies have also investigated its use as an immune adjuvant in combination with cancer-vaccine and chemotherapy research protocols in preclinical settings. More recent research has explored its role in immune-reconstitution markers following hematopoietic stem-cell transplantation models and in modulating immune responses in immunocompromised research models.